Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.72 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.72 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.72 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.72 |
| ▸ | CDK8 | P49336 | 1/20 | 0.67 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600309 | 0.90 | CDK8 (0.82) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1598998 | 0.87 | CDK8 (0.66) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1012719 | 0.87 | MAPK13 (0.78) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL12245421 | 0.86 | MAPK14 (0.88) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3621438 | 0.86 | CDK8 (0.67) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3939655 | 0.84 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL13199966 | 0.84 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1012997 | 0.84 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL4520038 | 0.84 | CDK8 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL4502798 | 0.84 | CDK8 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | MAPK14 694/4885MAPK13 670/4885MAPK12 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.